VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ZLAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ZLABZai Lab Limited
$18.41$2.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksZLABBalance Sheet

Zai Lab Limited (ZLAB) Balance Sheet

11Y historyFree accessUpdated daily

Financial stress is mounting as total debt surged from $15.2 million in 2023Q4 to $231.9 million in 2026Q1, contributing to a contraction in the equity base to $662.0 million.

ZLAB Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15
Total Current Assets944.73M1.02B1.05B939.61M1.12B1.5B1.22B292.46M269.14M230.61M84.09M13.23M
Cash & Short-Term Investments661.32M689.57M779.67M806.45M1.01B1.41B1.19B275.93M263.3M229.66M83.95M13.16M
Cash Only651.32M679.57M449.67M790.15M1.01B964.1M442.12M75.93M62.95M229.66M83.95M13.16M
Short-Term Investments10M10M330M16.3M0445M744.68M200M200.35M000
Accounts Receivable54.07M106.12M89.41M65.33M48.57M54.81M5.17M3.79M90K000
Days Sales Outstanding73.3884.1781.7989.4182.44138.6338.51106.56253.76---
Inventory85.96M74.75M39.88M44.83M31.62M18.95M13.14M6M3.82K000
Days Inventory Outstanding138.5142.7898.43170.76155.93132.4120.04584.6732---
Other Current Assets143.38M148.85M141.53M23M35.67M000-603000
Total Non-Current Assets151.01M153.1M135.27M96.69M95.8M109.08M81.6M62.69M32.84M19.02M4.81M710.11K
Property, Plant & Equipment64.65M66.54M69.47M68.69M78.77M58.28M47.14M36.86M20.77M11.98M2.66M707.58K
Fixed Asset Turnover6.90x6.92x5.74x3.88x2.73x2.48x1.04x0.35x0.01x---
Goodwill000000000000
Intangible Assets75.76M76.14M58.93M16.46M8.4M9.66M9.44M8.8M321.57K20.09K7K2.52K
Long-Term Investments1.11M03.12M9.22M6.43M15.61M1.28M2.4M3.15M1.65M500K0
Other Non-Current Assets7.15M7.02M3.75M2.32M2.2M25.53M23.75M14.62M8.88M5.5M3.06M0
Total Assets1.1B1.17B1.19B1.04B1.22B1.61B1.3B355.15M301.99M249.63M88.91M13.94M
Asset Turnover0.39x0.39x0.34x0.26x0.18x0.09x0.04x0.04x0.00x---
Asset Growth %27.78%-1.13%14.42%-15.07%-24.21%24.07%265.37%17.61%20.97%180.78%537.79%-
Total Current Liabilities392.98M416.17M299.38M203.07M139.84M192.9M98.04M46.63M48.84M12.07M5.17M3.94M
Accounts Payable126.17M141.61M100.91M112.99M65.97M126.16M62.64M22.66M37.43M8.97M523.34K1.45M
Days Payables Outstanding227.13270.5249.09430.43325.33881.5295.492.21K313.44K---
Short-Term Debt219.8M210.87M131.71M00006.45M3.64M000
Deferred Revenue (Current)55.96M27.33M0000000000
Other Current Liabilities18.38M36.35M6.35M5.35M4.05M4.42M4.57M2.39M2.5M778.96K4.05M2.14M
Current Ratio2.40x2.45x3.51x4.63x8.04x7.78x12.40x6.27x5.51x19.11x16.25x3.36x
Quick Ratio2.19x2.27x3.38x4.41x7.81x7.68x12.27x6.14x5.51x19.11x16.25x3.36x
Cash Conversion Cycle-15.25-43.55-68.86-170.26-86.96-610.48-36.94-1.52K-313.15K---
Total Non-Current Liabilities40.77M40.72M45.47M37.11M34.7M37.1M30.25M13.86M2.06M2.39M135.29M28.37M
Long-Term Debt12.11M13.38M0000000000
Capital Lease Obligations22.15M013.71M8.05M13.34M9.61M13.39M10.98M0000
Deferred Tax Liabilities000000000000
Other Non-Current Liabilities28.67M27.33M325K325K000000134.51M28.31M
Total Liabilities433.76M456.88M344.86M240.18M174.54M230M128.29M60.49M50.91M14.46M140.46M32.31M
Total Debt231.91M224.26M153.47M15.15M20.39M15.54M18.6M21.78M3.64M000
Net Debt-419.41M-455.31M-296.2M-775M-988.08M-948.56M-423.52M-54.15M-59.31M-229.66M-83.95M-13.16M
Debt / Equity0.35x0.31x0.18x0.02x0.02x0.01x0.02x0.07x0.01x---
Debt / EBITDA-1.02x-----------
Net Debt / EBITDA1.85x-----------
Interest Coverage-30.73x-33.26x-113.07x----1667.41x-662.20x-3489.82x---
Total Equity661.98M715.5M840.9M796.12M1.05B1.38B1.17B294.66M251.08M235.17M-51.55M-18.37M
Equity Growth %-7.01%-14.91%5.62%-23.86%-24.23%18.01%296.85%17.36%6.77%556.18%-180.63%-
Book Value per Share5.986.538.5082.38109.14148.39150.5645.7847.73108.11-54.62-21.13
Total Shareholders' Equity661.98M715.5M840.9M796.12M1.05B1.38B1.17B294.66M251.08M235.17M-51.55M-18.37M
Common Stock7K7K7K6K6K6K5K4K3.48K3K579533
Retained Earnings-2.68B-2.63B-2.45B-2.2B-1.86B-1.42B-713.6M-444.7M-249.63M-110.55M-60.17M-22.66M
Treasury Stock00-20.84M-20.84M-11.86M-4.28M000000
Accumulated OCI15.11M29.7M50.52M37.63M25.68M-23.64M-14.52M4.62M2.66M449.91K-698.53K-103.62K
Minority Interest000000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Persistent Capital Market Dependency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Capital Erosion Amidst Operational Losses

According to reported financial statements, Zai Lab's equity base has contracted from $796.1 million in 2023Q4 to $662.0 million by 2026Q1, reflecting a persistent trend of value erosion driven by the company's inability to achieve operational profitability while funding its extensive R&D and commercial infrastructure.

The consistent decline in equity, coupled with a ballooning accumulated deficit of $2.7 billion, suggests that the company is consuming its capital base to sustain its current business model. Investors should monitor whether this trajectory necessitates further dilutive financing, as the current rate of equity depletion appears unsustainable without a fundamental shift in revenue generation.

Rising Leverage Signals Financial Stress

Based on recent SEC filings, Zai Lab's total debt has surged from $15.2 million in 2023Q4 to $231.9 million in 2026Q1, indicating a shift toward debt-based financing as the company attempts to bridge the gap between its high operational burn rate and limited internal cash generation.

The increase in the debt-to-equity ratio to 0.35 suggests that the company is increasingly relying on leverage to maintain its operations. This rising debt burden warrants further investigation, as it introduces interest expense pressures that may further constrain the company's already negative operating margins.

Liquidity Buffer Faces Downward Pressure

As reported in quarterly filings, Zai Lab's cash position has declined from a peak of $790.2 million in 2023Q4 to $651.3 million in 2026Q1, while the current ratio has compressed from 4.63 to 2.40, signaling a tightening of the company's short-term financial flexibility.

While a current ratio of 2.40 still provides a nominal buffer, the rapid compression of this metric suggests that the company's liquidity is being consumed faster than it is being replenished. This trend may indicate that the firm is approaching a point where its cash runway could become a primary concern for stakeholders.

Intangible Asset Valuation Risks Loom

Data from the balance sheet shows that goodwill has increased from $16.5 million in 2023Q4 to $75.8 million in 2026Q1, which may indicate that the company is capitalizing acquisition costs that could be subject to future impairment if licensed assets fail to meet commercial expectations.

The accumulation of goodwill in a business model heavily reliant on external licensing suggests that the company's asset quality is sensitive to the success of its partners' clinical programs. Investors should be wary that these intangible assets may not represent tangible value if the underlying drug candidates face regulatory or market adoption hurdles.

ZLAB — Frequently Asked Questions

Quick answers to the most common questions about buying ZLAB stock.

What are the total assets of Zai Lab Limited (ZLAB)?

As of 2025, Zai Lab Limited (ZLAB) had total assets of $1.17B including $1.02B in current assets.

How much debt does Zai Lab Limited (ZLAB) have?

Zai Lab Limited (ZLAB) carries total debt of $224.3M, offset by $689.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Zai Lab Limited?

Zai Lab Limited (ZLAB) has total shareholders' equity (book value) of $715.5M ($6.53 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Zai Lab Limited's current ratio and liquidity?

Zai Lab Limited (ZLAB) reported a current ratio of 2.45x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.